Manjiri Sathe

Medicine · Health Sciences

15h-index3.9kcitations42works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(23), interferon and immune responses(8), Immunotherapy and Immune Responses(7), CAR-T cell therapy research(5), Psoriasis: Treatment and Pathogenesis(4)

Publications42 total

Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
2023Open Access
Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
2023Open Access
Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S2 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Table S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
2023Open Access
Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
2023Open Access
Supplementary Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Table S1 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S2 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Figure S3 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Data from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
2023Open Access
Figure S3 from STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors
2023Open Access
Supplementary Data from Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
2023Open Access
Conditional Deletion of Pdcd1 Identifies the Cell-Intrinsic Action of PD-1 on Functional CD8 T Cell Subsets for Antitumor Efficacy
Frontiers in Immunology·2021· 5 citedOpen Access
BET Bromodomain Inhibition Suppresses Human T Cell Function
ImmunoHorizons·2019· 18 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Sarah Javaid(20), Eric S. Muise(20), Brian J. Long(19), Terrill K. McClanahan(18), Sašo Čemerski(13), Samanthi A. Perera(12), Johnny E. Kopinja(12), Yanhong Ma(12), Jason Laskey(12), Kalyan Chakravarthy(12), Long Cui(12), Jeremy Presland(12), Ellen C. Minnihan(12), Heidi M. Ferguson(12), Jennifer Piesvaux(12), Bo‐Sheng Pan(12), Shu-Xia Zhao(12), Sharad Sharma(12), Hyun Chong Woo(12), Vincenzo Pucci(12)